KarMMa-2
Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
What's the purpose of the trial?
The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug bb2121 in combination with lenalidomide maintenance when given to participants with relapsed and refractory or high-risk multiple myeloma.
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C36.153613%2C-86.81075%7C32.812157%2C-96.8405%7C40.839802%2C-73.939301%7C33.792801%2C-84.319504%7C35.2062%2C-80.838203%7C40.8839%2C-74.055603%7C28.0644%2C-82.421501%7C38.638401%2C-90.263397%7C41.255507%2C-95.979724%7C42.363201%2C-71.068802%7C40.790001%2C-73.953697%7C47.607114%2C-122.309471%7C42.339699%2C-71.105003)
Participating Centers
There are 13 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Idecabtagene Vicleucel
- Talquetamab
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.